An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases

Trial Profile

An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment; Neurodegenerative disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 20 Jul 2017 Results (n=82) presented at the Alzheimer's Association International Conference 2017.
    • 20 Jul 2017 Results (n=122) presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results (n=64) presented at the Alzheimer's Association International Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top